Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People

The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for monoclonal antibodies to treat COVID-19 for certain patients. Clinicians will learn the FDA’s role in issuing EUAs for certain monoclonal antibodies, options for compassionate use, the process for ordering and distributing monoclonal antibodies, and current data on using monoclonal antibodies for both non-hospitalized and immunocompromised patients. Presenters will also cover preventing, diagnosing, and treating COVID-19 in immunocompromised patients, including the role of monoclonal antibodies, serologic testing, and potential third dose of COVID-19 vaccinations.

This video can also be viewed at

Recommend0 recommendationsPublished in US National Health Agency Sources

Related Articles

5 Essential Frameworks for Preventing Violent Child Death

The U.S. has a violent child death problem. Developing strategies to prevent violent child deaths death from firearms and traffic crashes is a demanding task that requires consideration of numerous upstream, interrelated, and tangential issues. To help safety advocates develop strategies to prevent violent child death, we compiled five frameworks to help: Understand and explain …
The post 5 Essential Frameworks for Preventing Violent Child Death appeared first on Salud America.

What Are the Risk and Protective Factors for Violent Child Death?

Gun violence and traffic crashes may seem like unpredictable events. But they are not random. They are systematic. Data reveal trends and patterns in gun violence and traffic crashes that can help us identify risk factors and protective factors. This is especially important for addressing violent child deaths. So what does the data show? Join …
The post What Are the Risk and Protective Factors for Violent Child Death? appeared first on Salud America.

Responses